Gilead Positions Inflammation and Immunology as Third Pillar of Growth Strategy

By Adam Feuerstein · STAT News · 2026-09-24

Gilead Positions Inflammation and Immunology as Third Pillar of Growth Strategy

According to STAT News, Gilead Sciences executives are signaling a major strategic pivot to investors by elevating their autoimmune pipeline to the same level of importance as their existing portfolios. Chief Financial Officer Andy Dickinson recently detailed a vision where these

According to STAT News, Gilead Sciences executives are signaling a major strategic pivot to investors by elevating their autoimmune pipeline to the same level of importance as their existing portfolios. Chief Financial Officer Andy Dickinson recently detailed a vision where these